Cuộc họp công bố kết quả kinh doanh quý 2/2026 của IRIDEX (IRIX): Tăng trưởng G6 và dòng tiền dương
Doanh thu quý 2/2026 của IRIDEX giảm 7% xuống còn 12,6 triệu USD, trong khi doanh thu Cyclo-G6 tăng 19%. Ban lãnh đạo tái khẳng định triển vọng doanh thu đạt mức 51 triệu đến 53 triệu USD.
IRIDEX Corporation is an ophthalmic medical technology company. The Company is developing, manufacturing, and marketing versatile laser-based medical systems, delivery devices and consumable instrumentation. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probe products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.